» Articles » PMID: 9180101

Long-term Estrogen Therapy Improves Vascular Function in Male to Female Transsexuals

Overview
Date 1997 Jun 1
PMID 9180101
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: This study sought to examine the effects of long-term estrogen therapy on vascular function in male to female transsexuals and to compare the findings with those observed in men and premenopausal women.

Background: Gender differences in coronary artery disease have largely been attributed to the beneficial effects of estrogen on vascular function and plasma lipids in women. However, the effects of estrogen on the male vasculature have not been widely studied.

Methods: We compared the effects of estrogen on vascular function in 14 male to female transsexuals, 14 age-matched men and 15 premenopausal women. Flow-mediated vasodilation and response to nitroglycerin were assessed in the brachial artery using noninvasive ultrasound.

Results: Flow-mediated vasodilation was similar in transsexuals and women but greater than that in men ([mean +/- SE] 11.5 +/- 1.3% and 9.4 +/- 1.1% vs. 5.2 +/- 1.0% respectively, p < 0.005). Responses to nitroglycerin were also greater in transsexuals and women than in men (21.6 +/- 1.7% and 21.0 +/- 0.9% vs. 14.5 +/- 1.2%, respectively, p = 0.0005). These differences persisted even after adjusting for vessel size. Despite similar total cholesterol levels, transsexuals had high density lipoprotein cholesterol levels similar to those in women and greater than those observed in men (1.76 +/- 0.12 and 1.82 +/- 0.11 mmol/liter vs. 1.35 +/- 0.07 mmol/liter, respectively, p < 0.005). Moreover, triglyceride levels were greater in transsexuals than in men and women, and low density lipoprotein cholesterol (LDL-C) particle size was smaller (25.7 +/- 0.2 nm vs. 26.2 +/- 0.1 and 26.6 +/- 0.1 nm, respectively, p = 0.0001). Serum testosterone (an index of estrogen therapy in transsexuals) was markedly suppressed in transsexuals and similar to that in women. Univariate analysis revealed that there was a strong inverse correlation between serum testosterone and flow-mediated vasodilation (r(s) = -0.48, p < 0.005). Multivariate analysis revealed that the best combination of predictors of flow-mediated vasodilation was serum testosterone, vessel size and LDL-C (R2 = 0.3, p < 0.005).

Conclusions: Long-term estrogen therapy appears to improve vascular function in male to female transsexuals and occurs despite higher triglyceride levels and the presence of small, dense LDL-C. The beneficial effects of estrogen are not gender specific or solely mediated through endothelium-derived nitric oxide.

Citing Articles

Getting to the Heart of the Matter: Exploring the Intersection of Cardiovascular Disease, Sex and Race and How Exercise, and Gut Microbiota Influence these Relationships.

Guers J, Heffernan K, Campbell S Rev Cardiovasc Med. 2025; 26(2):26430.

PMID: 40026503 PMC: 11868917. DOI: 10.31083/RCM26430.


Gender-affirming hormone therapy: effects on cardiovascular risk and vascular function.

McGinley K, Lucas-Herald A, Connelly P, Delles C Endocr Connect. 2024; .

PMID: 39585765 PMC: 11728916. DOI: 10.1530/EC-24-0222.


Impact of Gender-Affirming Hormonal Therapy on Cardiovascular Risk Factors in Transgender Health: An Updated Meta-Analysis.

Rahman S, Manasrah N, Kumar N, Hamza M, Sharma A, Patel N JACC Adv. 2024; 3(10):101265.

PMID: 39309657 PMC: 11414688. DOI: 10.1016/j.jacadv.2024.101265.


Metabolic benefits afforded by estradiol and testosterone in both sexes: clinical considerations.

Mauvais-Jarvis F, Lindsey S J Clin Invest. 2024; 134(17).

PMID: 39225098 PMC: 11364390. DOI: 10.1172/JCI180073.


Endogenous androgens, coronary atheroma and remodeling in women with suspected ischemic heart disease: A report from the Women's Ischemia Syndrome Evaluation (WISE) study.

Ranasinghe S, Jain A, Taha Y, Handberg E, Johnson B, Bittner V Am Heart J Plus. 2024; 43:100411.

PMID: 38873103 PMC: 11169945. DOI: 10.1016/j.ahjo.2024.100411.